Vylor (NYSE:VYLR – Get Free Report) was upgraded by UBS Group to a “strong-buy” rating in a research note issued to investors on Monday, Zacks reports.
VYLR has been the topic of a number of other research reports. KeyCorp assumed coverage on Vylor in a report on Wednesday, October 7th. They set a “sector weight” rating and a $78.00 price target on the stock. Zacks Research raised Vylor to a “hold” rating in a report on Monday, October 5th. Morgan Stanley began coverage on Vylor in a report on Friday, October 2nd. They set an “overweight” rating and a $85.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Vylor in a research note on Thursday, October 8th. They issued a “buy” rating and a $87.00 price objective on the stock. Finally, Wolfe Research upgraded shares of Vylor to a “strong-buy” rating in a research report on Thursday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $83.36.
Read Our Latest Stock Report on Vylor
Vylor Stock Performance
Vylor Company Profile
Vylor Inc is a seed and genetics company. It develops and supplies germplasm for farmers to improve crop health and produce higher yields. Vylor Inc is based in JOHNSTON, Iowa.
Read More
- Five stocks we like better than Vylor
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Vylor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vylor and related companies with MarketBeat.com's FREE daily email newsletter.
